Abstract
Summary: Type 1 interferon‐β (T1IFN‐β) is an innate cytokine and the first‐choice therapy for multiple sclerosis (MS). It is still unclear how T1IFN‐β, whose main function is to promote innate immunity during infections, plays a beneficial role in autoimmune disease. Here we show that T1IFN‐β promoted the expansion and function of invariant natural killer (iNKT) cells, an innate T‐cell subset with strong immune regulatory properties that is able to prevent autoimmune disease in pre‐clinical models of MS and type 1 diabetes. Specifically, we observed that T1IFN‐β treatment significantly increased the percentages of Vα24+ NKT cells in peripheral blood mononuclear cells of MS patients. Furthermore, iNKT cells of T1IFN‐β‐treated individuals showed a dramatically improved secretion of cytokines (interleukins 4 and 5 and interferon‐γ) in response to antigenic stimulation compared to iNKT cells isolated from the same patients before T1IFN‐β treatment. The effect of T1IFN‐β on iNKT cells was mediated through the modulation of myeloid dendritic cells (DCs). In fact, DCs modulated in vivo or in vitro by T1IFN‐β were more efficient antigen‐presenting cells for iNKT cells. Such a modulatory effect of T1IFN‐β was associated with up‐regulation on DCs of key costimulatory molecules for iNKT (i.e. CD80, CD40 and CD1d). Our data identified the iNKT cell/DC pathway as a new target for the immune regulatory effect of T1IFNs in autoimmune diseases and provide a possible mechanism to explain the clinical efficacy of T1IFN‐β in MS.

This publication has 50 references indexed in Scilit: